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Consumers in Shock:
How Federal Government Overregulation Led Mylan to
Acquire a Monopoly over Epinephrine Autoinjectors
By: Nicole E. O’Toole*
I. INTRODUCTION
The freedoms and opportunities the United States of America provides
allows Americans of any gender, race, religion, ethnicity, education,
socioeconomic status, or background to follow their dreams and achieve
success. Marco Rubio, the son of a bartender and a housekeeper fleeing
the Cuban Revolution in 1956, grew up to become an attorney, published
author, United States Senator and Presidential nominee.1 Oprah Winfrey,
born to a single African American teenage mother living in poverty, grew
up to be the second-richest self-made woman in the world.2
While it is often argued that Republicans and Democrats have the same
end goal, the most basic and foundational difference between the parties
in present-day American politics is the way in which each party believes
Americans are best able to achieve success. Typically, Democrats
promote systems such as welfare benefits in order to help citizens who
are in a more challenging economic position. 3 On the other side,
Republicans usually favor a more limited role of government, including
less regulation on business and a laissez-faire free market philosophy.4
Senior research fellow at the Mercatus Center at George Mason
University Matthew Mitchell illustrates the idea of similar end goals of
opposing parties as it applied to the 2008 financial bailouts:
Despite the ideological miles that separate them, activists in the Tea Party
and Occupy Wall Street movements agree on one thing: both condemn
the recent bailouts of wealthy and well-connected banks. To the Tea
Partiers, these bailouts were an unwarranted federal intrusion into the free
*

Nicole O’Toole is a Class of 2018 Juris Doctor Candidate at DePaul University College of Law
and Editor-in-Chief of the DePaul Business and Commercial Law Journal. She earned a B.A. in
Political Science and minors in Business Administration and Global Studies from Saint Mary’s
College in 2015. She would like to thank her parents, James and Elizabeth O’Toole, for their
constant support.
1 Biography, MARCO RUBIO, http://www.rubio.senate.gov/public/index.cfm/biography (last visited
Mar. 26, 2017).
2 Oprah Winfrey Profile, FORBES, http://www.forbes.com/profile/oprah-winfrey/ (last visited Mar.
26, 2017).
3 Ryan C. Fuhrmann, What are the main differences between the Republican and Democratic
approaches to regulating the economy?, INVESTOPEDIA,
http://www.investopedia.com/ask/answers/regulating-economy.asp (last visited Mar. 26, 2017).
4 Id.
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market; to the Occupiers, they were a taxpayer-financed gift to the
wealthy executives whose malfeasance brought on the financial crisis. To
both, the bailouts smacked of cronyism.5

The notion that opposing ideologies could have similar views on
corruption could be said about the topic of this Note: the effects of the
federal government’s role on the epinephrine autoinjector market. Both
Republicans and Democrats have expressed their disdain over the rapid
price increase of epinephrine autoinjectors in recent years, and what it
means for those in need of the life-saving drug. Democratic Senator
Bernie Sanders said of the issue, “Mylan’s near monopoly on the
epinephrine autoinjector market has allowed [Mylan] to increase prices
well beyond those that are justified by any increase in the costs of
manufacturing the EpiPen.”6 Republican Senator Rand Paul penned an
op-ed piece on the issue outlining his very similar frustrations: “The
controversy over the price of the EpiPen has reached a fever pitch as
prices have risen by more than 400% and costing up to $600 for two of
the pens. To fully comprehend the outrage of this price…the epinephrine
included in the EpiPen costs less than ten dollars retail.”7 While Senator
Sanders and Senator Paul are typically in disagreement on most major
political stances, their shared frustration over the epinephrine autoinjector
market shows how bipartisan the issue is.
Proponents of the fiscally conservative point of view, such as Ann
Coulter, have described their support for a free market economy as
follows: “everything provided by the free market over time will become
better and cheaper...everything provided by the government over time
will become more expensive and worse.”8 Many Republicans like to use
the example of the Affordable Care Act (“Obamacare”) as an example of
a “failed” federal attempt to police the marketplace.9 Once the healthcare
industry was regulated by the federal government, Republicans have
argued, the cost of insurance premiums have increased the cost of
Matthew Mitchell, GEORGE MASON U. MERCATUS CTR., The Pathology of Privilege: The
Economic Consequences of Government Favoritism, 1 (2012),
http://mercatus.org/sites/default/files/The_Pathology_of_Privilege-Final_2.pdf.
6 Senators Raise Concerns About Mylan’s EpiPen Price Hike, BERNIE SANDERS (Aug. 30, 2016),
https://www.sanders.senate.gov/newsroom/press-releases/senators-raise-concerns-about-mylansepipen-price-hike.
7 Rand Paul, Sen. Rand Paul: EpiPen Scandal Is a Perfect Example of Crony Capitalism, TIME,
(Sept. 7, 2016), http://time.com/4482179/sen-rand-paul-epipen-scandal/.
8 Will Dooling, Koch's Americans for Prosperity Brings Ann Coulter to Madison in a Last-Minute
Push to Stop “Obama's Failing Agenda”, PRWATCH CTR. FOR MEDIA & DEMOCRACY (Nov. 5,
2012, 8:59 PM), http://www.prwatch.org/news/2012/11/11842/americans-prosperity-brings-anncoulter-madison-last-minute-push-stop-obamas-fail.
9 Patient Protection and Affordable Care Act, 111th Cong. (2009), H.R.3590, CONGRESS,
https://www.congress.gov/bill/111th-congress/house-bill/3590.
5
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medical services by an estimated twenty-four percent,10 which caused a
number of previously successful carriers to flee the market.11 Advocates
of this theory credit the optimization of quality goods in a given market
to healthy competition.12 As Mitchell describes it: “markets tend to be
competitive when, most important[ly], there are no barriers to entering or
exiting the industry.”13
The philosophy that federal government intervention increases
costs and decreases options and values available to consumers can be
analyzed across a plethora of markets. Specifically, this Note will focus
on the epinephrine autoinjector market. An epinephrine autoinjector,
more commonly known by Mylan’s brand called the “EpiPen,”14 is most
often used for the treatment of anaphylaxis, which is a serious allergic
reaction that may cause death.15 Today, the EpiPen is considered the
“Kleenex” of epinephrine autoinjectors as it is estimated to control over
ninety percent of the market share.16 From a Darwinist perspective it
would appear that because the EpiPen controls most of the market, it
must be the most superior product available to consumers. However, as
the succeeding sections will cover, this is likely not the case, and there is
ample evidence to prove that EpiPen’s market success is largely due to
government regulations and mandates. This Note will also focus on the
2014 United States District Court case JHP Pharmaceuticals v. Hospira,
which dealt with labeling issues surrounding epinephrine autoinjectors.17
It is quite possible that safer, more efficient, and more affordable
versions of the EpiPen may be available to consumers today if it were not
for these government interventions.

Brian Blase, Overwhelming Evidence That Obamacare Caused Premiums To Increase
Substantially, FORBES (July 28, 2016),
http://www.forbes.com/sites/theapothecary/2016/07/28/overwhelming-evidence-that-obamacarecaused-premiums-to-increase-substantially/#36cee92946e3.
11 Editorial: Why Obamacare failed, CHI. TRIB. (Sept. 9, 2016),
http://www.chicagotribune.com/news/opinion/editorials/ct-obamacare-fail-health-care-insurancemedicine-0911-jm-20160909-story.html.
12 Matthew Mitchell, GEORGE MASON U. MERCATUS CTR., The Pathology of Privilege: The
Economic Consequences of Government Favoritism, 3 (2014),
http://mercatus.org/sites/default/files/The_Pathology_of_Privilege-Final_2.pdf.
13 Id.
14 Important Safety Information, EPIPEN, https://www.epipen.com/ (last visited Mar. 26, 2017).
15 Chitra Dinakar, Anaphylaxis in Children: Current Understanding and Key Issues in Diagnosis
and Treatment, US NAT’L LIBR. OF MED. NAT’L INSTS. OF HEALTH, (Jul. 20, 2012),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492692/.
16 Ben Popken, Lawmakers Accuse Mylan CEO of ‘Rope-a-Doping’ on EpiPen Prices, NBC NEWS
(Sept. 21, 2016), http://www.nbcnews.com/business/consumer/lawmakers-grill-mylan-ceo-fdaepipen-price-hike-n651201.
17 JHP Pharmaceuticals v. Hospira, 52 F.Supp.3d 992 (C.D. Cal. 2014).
10
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As this note will discuss, courts should decline to follow the
overall ruling in JHP Pharmaceuticals v. Hospira18 because holding that
a court is unable to decide a case based on a separate federal agency
simply a waste of litigation. However, courts should consider the line of
reasoning that where there is no proof that a non-FDA approved drug is
any less safe than an FDA-approved drug, the non-approved drug should
not be precluded from entering the market.

II. BACKGROUND
This section provides background information concerning the
economic and legal support for the conclusion that the federal
government’s role in Mylan’s monopoly over the epinephrine
autoinjectors has created a burden for consumers. The first subsection
provides a general background on epinephrine autoinjectors. 19 The
second subsection provides a general background on monopolies.20 The
third subsection provides a background on Mylan’s monopoly over the
epinephrine autoinjector market, and the government’s role in the
creation of the monopoly.21 Finally, the fourth subsection provides a
background on JHP Pharmaceuticals and its legal implications for
Mylan’s monopoly over the epinephrine autoinjector market.22

A. Background on Epinephrine Autoinjectors
Epinephrine is used to treat anaphylaxis, a serious, systemic
allergic reaction that is rapid in onset and can cause death.23 Epinephrine
helps relieve the life-threatening symptoms of anaphylaxis (such
hypotension, shock, and upper airway obstruction) via its alphaadrenergic effects.24 Delayed administration of epinephrine causes an
increased risk of death; therefore it is essential for patients at risk for
anaphylaxis to be educated regarding the appropriate administration
technique for epinephrine autoinjector devices.25 The most notable users

Id.
See infra notes 23-46 and accompanying text.
20 See infra notes 47-57 and accompanying text.
21 See infra notes 58-124 and accompanying text.
22 See infra notes 125-139 and accompanying text.
23 Brice Labruzzo Mohundro and Michael Marlan Mohundro, Important Considerations When
Dispensing Epinephrine Auto-Injector Devices, PHARMACY TIMES, (Sept. 22, 2010),
http://www.pharmacytimes.com/p2p/p2pepinephrine-0910.
24 Id.
25 Id.
18
19
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of these devices are children with severe food allergies who may be
inadvertently exposed to such foods at school.26

1. Background on the EpiPen
Presently, the leading brand of epinephrine autoinjectors in Mylan’s
version called the EpiPen. 27 Mylan has been the subject of much
controversy in the past few years, as the price of the EpiPen has
drastically increased.28 Today, a pack of two EpiPens costs about $600.29
For reference, the amount of epinephrine in the devices only cost about
ten dollars30, and that same two-pack of EpiPens only cost consumers
$100 in 2008.31 Most insurers only cover one pair of EpiPens each
year.32 However, parents with children who have serious food allergies
are usually suggested to keep one pair of EpiPens at school, one pair at
home, and a pair for each parent to carry with them.33 Furthermore, the
suggested shelf life for an EpiPen in 2016 is about eighteen months,
compared to a recommended shelf life of twenty-seven months in 2002.34
EpiPens must be kept at room temperature, meaning they cannot be left
in a vehicle on during extremely hot or cold weather, and must be
protected from light and water.35 If there is even a possibility an EpiPen
has been compromised by expiration, temperature, light, or water, it must
be thrown away and cannot be used.36 Taking into consideration all of
the associated risks, families could be paying upwards of $2,400 out of
pocket per year for this life-saving drug.

Meghana Keshavan, Can anyone shake the EpiPen monopoly? Here’s one company that’s trying,
STATNEWS, (Jul. 7, 2016), https://www.statnews.com/2016/07/07/epipen-monopoly-mylanwindgap-medical/.
27 Id.
28 Id.
29 Id.
30 Randal H. Paul, Sen. Rand Paul: EpiPen Scandal Is a Perfect Example of Crony Capitalism,
TIME, (Sept. 7, 2016), http://time.com/4482179/sen-rand-paul-epipen-scandal/.
31 Anaphylactic Political Shock, WALL ST. J., Pg. A10, (Aug. 25, 2016),
https://www.wsj.com/articles/anaphylactic-political-shock-1472078239.
32 Meghana Keshavan, Can anyone shake the EpiPen monopoly? Here’s one company that’s trying,
STATNEWS, (Jul. 7, 2016), https://www.statnews.com/2016/07/07/epipen-monopoly-mylanwindgap-medical/.
33 Id.
34 Carolyn Y. Johnson, Why EpiPens expire so quickly, WASH. POST, (Sept. 27, 2016),
https://www.washingtonpost.com/news/wonk/wp/2016/09/27/why-epipens-expire-soquickly/?utm_term=.2068a5e5e357.
35 Frequently Asked Questions, EPIPEN http://www.epipen.ca/en/about-epipen/frequently-askedquestions (last visited Mar. 27, 2017).
36 Id.
26
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2. Alternative Proposals to the EpiPen
Adrenaclick is currently EpiPen’s main, and much cheaper,
competition, but the product is not always covered by insurance and was
prescribed fewer than 1,000 times in the United States last year.37 CVS
Health recently began to market on the drug’s behalf and is hoping to
price the generic version of the drug at just $110 for a two-pack.38 Many
drug manufacturers have proposed their plans for competing epinephrine
autoinjectors. Chris Stepanian, CEO of Windgap Medical, a Boston
startup is in the process of creating a smaller, lighter epinephrine
autoinjector, called Abiliject, could be ready for review by 2018. 39
Stepanian explained his hope for the Abiliject would make the injector
about forty percent smaller than the EpiPen, designed to fit in a pocket.40
He also says Windgap is working on temperature stability, “so even if
you leave it in your car on a hot and sunny day, you don’t have to throw
away the device.”41 Windgap’s other goals for the Abiliject are a longer
shelf life than the EpiPen and they are hoping to make the Abiliject more
intuitive to use.42
As outrage continues to grow over Mylan price increases, several
companies have proposed their ideas for alternatives for considerably
more affordable options, such as having families obtain syringes that a
doctor pre-fills with epinephrine. 43 The drug manufacturer Sanofi
introduced its own version of an epinephrine autoinjector, the Auvi-Q, in
2012.44 The Auvi-Q was novel because it was a “talking autoinjector,” in
which the device instructed users through the entire process of
injection.45 This aspect of the Auvi-Q was especially beneficial because
oftentimes the person suffering an anaphylactic attack is not the one
administering a dose of epinephrine. The Auvi-Q allowed a friend,
family member, teacher, co-worker, peer, or even complete stranger
witnessing somebody who is having an allergic reaction and unable to
Rand Paul, Sen. Rand Paul: EpiPen Scandal Is a Perfect Example of Crony Capitalism, TIME,
(Sept. 7, 2016), http://time.com/4482179/sen-rand-paul-epipen-scandal/.
38 Brad Tuttle, Sick of $600 EpiPen Prices? A Major Retailer Has an Alternative for Only $10,
TIME, (Jan. 12, 2017), http://time.com/money/4632964/cvs-epipen-alternative-adrenaclick/.
39 Meghana Keshavan, Can anyone shake the EpiPen monopoly? Here’s one company that’s trying,
STATNEWS,, (Jul. 7, 2016), https://www.statnews.com/2016/07/07/epipen-monopoly-mylanwindgap-medical/.
40 Id.
41 Id.
42 Id.
43 Rand Paul, Sen. Rand Paul: EpiPen Scandal Is a Perfect Example of Crony Capitalism, TIME
(Sept. 7, 2016), http://time.com/4482179/sen-rand-paul-epipen-scandal/.
44 Susan Scutti, Epipen Competitor Alternatives Auvi-Q Returning Soon, CNN (Oct. 27, 2016),
http://www.cnn.com/2016/10/26/health/auvi-q-epinephrine-autoinjector-returns/.
45 Id,
37
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self-inject to help properly administer the dose of epinephrine. However,
Auvi-Q was recalled in 2015 amid concerns that the product was not
delivering an accurate dosage of epinephrine.46
While the EpiPen tackles the most basic purpose of epinephrine
autoinjectors (to allow users suffering from an anaphylactic attack to
administer a dose of epinephrine), many American companies have
tremendous ideas that would specialize, fix, or perfect the current state of
epinephrine autoinjectors.

B. General Background on Monopolies
The Encyclopædia Britannica’s definition for the Hasbro, Inc. board
game “Monopoly” is a great depiction of the economic phenomenon:
“Monopoly [is a] real-estate board game…in which the player’s goal is to
remain financially solvent while forcing opponents into bankruptcy.”47
As players as young as eight years old have discovered, the way to win
the game is to acquire all of the properties possible, and leave one’s
opponents with nothing. This way, the winner can control what players
do and how much they pay. This simplistic explanation of a monopoly is
critical to understanding the effects of Mylan having significant market
power because they are the only – or near only – supplier of a particular
product.
There are typically two ways an entity acquires such economic power
that they face little or no competition in the territories where they
operated: by a de jure or a de facto monopoly.48 Most of the great
American monopolies of the early nineteenth century were de jure, or
created by the government.49 Most twentieth century monopolies were
de facto, or created by technology, patents, and the marketplace.50 An
example of a de jure monopoly is the United States Postal Service
(“USPS”). USPS has a monopoly of the letter-delivery industry that
dates back to 1775 when Benjamin Franklin was named the first
American Postmaster General in order to facilitate the country’s need for
communication between army commanders, first representatives, and

Id.
Monopoly Board Game, ENCYCLOPEDIA BRITANNICA (Jul. 8, 2005),
https://www.britannica.com/topic/Monopoly-board-game.
48 Luis Aníbal Avilés, Public Utilities And The European Union's “Services Of General Economic
Interest”: Feudal Origins Of Their Monopoly Powers, 4 U. P.R. BUS. L.J. 76 (2012).
49 Herbert Hovenkamp, Technology, Politics, And Regulated Monopoly: An American Historical
Perspective, 62 TEX. L. REV. 1263, (1984).
50 Id.
46
47
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constituents. 51 Congress protected USPS’s monopoly in 1949 when
Congress wrote:
Whoever establishes any private express for the conveyance of letters or
packets, or in any manner causes or provides for the conveyance of the
same by regular trips or at stated periods over any post route which is or
may be established by law . . .shall be fined . . . or imprisoned . . . or
both.52

By contrast, true de facto monopolies are few and far between. The
best example of a de facto monopoly is Sirius XM Radio. When rival
companies XM Satellite Radio Holdings Inc. and Sirius Satellite Radio
merged in 2007, 53 the new company, Sirius XM Radio, acquired a
monopoly over the satellite radio market.54
Mylan’s success in the epinephrine autoinjector market is attributed to
some government regulation, such as the FDA approval process and the
School Access to Emergency Epinephrine Act, as later sections will
explore.
While Mylan is not the sole supplier of epinephrine
autoinjectors, it does control over ninety percent of the market, therefore
it acquires a near-monopoly over the industry, rather than an actual
monopoly. This is not uncommon as most other industry leaders are
near-monopolies. These companies may not control 100% of the market,
but they control a majority of it, so they still reap the benefits of price
setting in a given industry.
Such near-monopoly examples are Netflix, having over fifty-percent of
the market share for video streaming services, and Google, having
seventy-percent of the market share for domestic search engines.55 The
issue then becomes whether companies gain near-monopoly status by
their organic success in the market, such as Netflix and Google, or due to
some sort of government intervention. For example, many broadband
providers and electric utility providers have geographic-specific nearmonopolies because of government contracts. An example of this type of
quasi-de jure near-monopoly is ComEd in the Chicagoland area.56 While
the City of Chicago did not create ComEd to be the sole electric utility
Universal Service and the Postal Monopoly: A Brief History, USPS, (2008),
https://about.usps.com/universal-postal-service/universal-service-and-postal-monopolyhistory.pdf.
52 18 U.S.C. § 1696(a) (1948).
53 David Ellis & Paul La Monica, XM, Sirius announce merger, CNN (Feb 20, 2007),
http://money.cnn.com/2007/02/19/news/companies/xm_sirius/index.htm?cnn=yes.
54 Id.
55 The Next 7 American Monopolies, BUS. INSIDER, (Nov. 18, 2010),
http://www.businessinsider.com/the-next-7-american-monopolies-2010-11?op=1/#streamingmovies-future-rental-monopoly-opportunity-in-the-making-1.
56 City to Return to ComEd for Electricity Contract, ABC, (Apr. 24, 2015),
http://abc7chicago.com/news/city-to-return-to-comed-for-electricity-contract/680651/.
51
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provider, ComEd’s contract with the city interferes with other
companies’ ability to infiltrate the market. 57 Therefore, ComEd’s
monopoly power in Chicago is due to government intervention rather
than organic success in the electric utility market. Now that the general
foundation of monopolies has been laid, a more thorough analysis of
Mylan’s monopoly in the epinephrine autoinjector drug market may be
done.

C. Economic Background on Mylan’s Monopoly
Mylan recently generated much controversy involving the massive
price increase of their allegedly generic brand of the epinephrine
autoinjector drug, the EpiPen. There are two factors playing into
Mylan’s near-monopoly on the epinephrine autoinjector drug market.
First, the School Access to Emergency Epinephrine Act (“SAEEA”)
enacted by Congress in 2013 requiring all elementary and secondary
schools in a state to maintain a supply of FDA-approved epinephrine.58
The mandated purchase of epinephrine drugs by schools and lack of
ability for other drug companies to sell their epinephrine drugs essentially
created a monopoly for Mylan.59 This gave Mylan the ability to hike up
its prices, creating a burden on consumers to attain an adequate supply of
the drug they need. The second is the incredibly tedious United States
Food and Drug Administration (“FDA”) approval process and subsequent
heavy backlog of drugs awaiting approval, which makes it nearly
impossible for alternatives to the EpiPen to get approved.60

1. The School Access to Emergency Epinephrine Act
The first way Mylan achieved the ability to hike up its price of the
EpiPen is through the enactment of the SAEEA. Mylan was under
criticism after it was revealed that it spent $4 million to lobby congress
for the 2013 Act.61 “The company’s profits soared twenty-two and one
Id.
School Access to Emergency Epinephrine Act, 113th Congress (2014), S.1503, CONGRESS,
https://www.congress.gov/bill/113th-congress/senate-bill/1503.
59 Id.
60 Sydney Lupkin, FDA Fees On Industry Haven’t Fixed Delays In Generic Drug Approvals, NPR,
(Sept. 1, 2016), http://www.npr.org/sections/health-shots/2016/09/01/492235796/fda-fees-onindustry-havent-fixed-delays-in-generic-drug-approvals.
61 Jacob Maslow, EpiPen Maker Mylan Flees Overseas to Avoid Taxes After 2013 School Access to
Emergency Epinephrine Act, HUFFINGTON POST, (Aug. 31, 2016),
http://www.huffingtonpost.com/entry/epipen-maker-mylan-flees-overseas-to-avoid-taxesafter_us_57c2b82ae4b0b01630df8490.
57
58
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half percent between 2013 and 2015.” 62 Chief Executive Officer of
Mylan, Heather Bresch, who was behind the price raise of the EpiPen in
2015 received a $19 million salary.63 Mylan was also under scrutiny
because Bresch is the daughter of Democratic Senator from West
Virginia Joe Manchin III, a member of the 113th Congress that passed the
SAEEA.64 While Mylan’s efforts in lobbying for the SAEEA were
suspicious, the importance of the Act is widely undisputed. Anaphylactic
shock is so rapidly-onset and potentially life threatening, so the need to
act quickly is very high.65 Therefore, SAEEA is very important in order
to ensure that schools are prepared to treat children who may go into
anaphylactic shock.
Just prior to SAEEA’s enactment, it was estimated that nine and onehalf percent of American children suffered from Asthma, and between
four and six percent of American children were affected by food
allergies; either of which can strike in an instant, and have life
threatening consequences.66 Congress and drug companies stepped in to
address the concern for parents of children with asthma and severe food
allergies (among other ailments which may trigger anaphylaxis).67 In
2012, Mylan announced the EpiPen4Schools program, providing the drug
for free. 68 To date, Mylan has given away more than 700,000 free
EpiPens to schools nationwide.69 After Mylan’s successful lobbying
efforts culminated in the passage of the SAEEA in 2013, it has not been
reported that Mylan has continued to provide schools with free EpiPens.70
Mylan’s lobby efforts to increase the availability of epinephrine
autoinjectors in United States schools did not go unnoticed.71 “Although
these legislative efforts were not supposed to benefit a particular
company, the brand has such a lock on the market that when President
Barack Obama signed the School Access to Emergency Epinephrine Act

Id.
Id.
64 Id.
65 Death From Anaphylaxis is a Reassuringly Unusual Outcome, AAAAI, (Dec. 13, 2013).
https://www.aaaai.org/global/latest-research-summaries/Current-JACI-Research/death-anaphylaxis.
66 Valerie Jarrett, President Obama Signs New EpiPen Law To Protect Children with Asthma and
Severe Allergies, And Help Their Families To Breathe Easier, WHITE HOUSE, (Nov. 13, 2013),
https://obamawhitehouse.archives.gov/blog/2013/11/13/president-obama-signs-new-epipen-lawprotect-children-asthma-and-severe-allergies-an.
67 Carolyn Y. Johnson and Catherine Ho, How Mylan, the EpiPen company, maneuvered to create
a virtual monopoly, CHI. TRIB, (Aug. 25, 2016), http://www.chicagotribune.com/business/ct-mylanepipen-monopoly-20160825-story.html.
68 Id.
69 Id.
70 Id.
71 Id.
62
63
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in 2013, a news announcement simply called it the ‘EpiPen Law,’” an
article in the Chicago Tribune explained in August 2016.72
Democratic Senator Richard Durbin from Illinois introduced the
SAEEA to the Senate on September 12, 2013.73 Officially, the Act
“amends the Public Health Service Act…to give an additional preference
to a state that allows self-administration of asthma and anaphylaxis
medication.”74 The Act:
Requires elementary and secondary schools in such a state to: (1) permit
trained personnel to administer epinephrine to a student reasonably
believed to be having such a reaction, (2) maintain a supply of
epinephrine in a secure location that is easily accessible to trained
personnel for such treatment, and (3) have in place a plan for having on
the school premises during operating hours one or more designated
personnel trained in administration of epinephrine.75

These “additional preferences” included financial incentives to states
that enact their own mandates for schools to stock epinephrine
autoinjectors.76 Many have argued that mandating a state “maintain a
supply of epinephrine in a secure location that is easily accessible to
trained personnel for such treatment”77 was the golden ticket for Mylan,
because the EpiPen was the most well-known epinephrine autoinjector
available, so it was the optimal choice for schools.78 If schools are
required to supply a drug that must be administered by bystanders in
emergency situations, it makes the most sense that they would supply a
drug that the majority of children and staff are familiar with. “That was a
Trojan horse,” said David Maris, a Wells Fargo analyst.79 “That was,
‘Let’s get it in schools to help people,’ but it helps market EpiPen and
promote it as the trusted product in schools.”80

Carolyn Y. Johnson and Catherine Ho, How Mylan, the EpiPen company, maneuvered to create
a virtual monopoly, CHI. TRIB, (Aug. 25, 2016), http://www.chicagotribune.com/business/ct-mylanepipen-monopoly-20160825-story.html.
73 School Access to Emergency Epinephrine Act, 113th Congress (2014), S.1503, CONGRESS,
https://www.congress.gov/bill/113th-congress/senate-bill/1503.
74 Id.
75 Id.
76 Carolyn Y. Johnson and Catherine Ho, How Mylan, the EpiPen company, maneuvered to create
a virtual monopoly, CHI. TRIB, (Aug. 25, 2016), http://www.chicagotribune.com/business/ct-mylanepipen-monopoly-20160825-story.html.
77 School Access to Emergency Epinephrine Act, 113th Congress (2014), S.1503, CONGRESS,
https://www.congress.gov/bill/113th-congress/senate-bill/1503.
78 Carolyn Y. Johnson and Catherine Ho, How Mylan, the EpiPen company, maneuvered to create
a virtual monopoly, CHI. TRIB, (Aug. 25, 2016), http://www.chicagotribune.com/business/ct-mylanepipen-monopoly-20160825-story.html.
79 Id.
80 Id.
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R. Adams Dudley, a pulmonologist at the University of California at
San Francisco said of the monopoly: “[Mylan’s] most brilliant maneuver,
clearly, was giving [EpiPens] away to schools and making it the thing
that they could say, ‘Well, the nurse knows how to use it.’” 81 As
evidenced by their decision to use EpiPens, this logic made sense to
school administrators, nurses, and parents. NBC News Senior Staff
Writer Ben Popken said of the issue: “Mylan has made its crown jewel
product ubiquitous…. What are the parents afraid of? Their child will be
away from them, and they won't be there to use [an epinephrine
autoinjector]…. If they can say the school nurse knows how to use an
EpiPen; she's never seen an Adrenaclick.... It's just a fear thing.”82 The
combination of this government intervention, the SAEEA, along with the
complex and lengthy FDA approval process has allowed Mylan to create
a monopoly over the epinephrine autoinjectors.

2. FDA New Drug Approval Process
There are two generally unchallenged facts that are important to clarify
in order to accurately lay the foundation for a background into the FDA
approval process: (1) a federally-regulated approval process is critical to
ensure that patients are receiving safe drugs, and (2), because of this,
American consumers benefit from having access to the safest and most
advanced pharmaceutical system in the world.83 The main consumer
watchdog for the American pharmaceutical system is the Center for Drug
Evaluation and Research (“CDER”), a division of the FDA. 84 The
CDER’s main role is to evaluate new drugs before they can be sold, in
order to prevent quackery and ensure that doctors and patients are
provided with the necessary information they need to use medicines
wisely.85
When a new drug wants to enter the market in the United States, the
first step is to test the drug to prove that it is safe and effective for its
intended use.86 In order to do so, the CDER assembles an independent
and unbiased team of physicians, statisticians, chemists, pharmacologists,
and other scientists to review the company’s data and proposed
Id.
Ben Popken, Lawmakers Accuse Mylan CEO of ‘Rope-a-Doping’ on EpiPen Prices, NBC NEWS,
(Sept. 21, 2016), http://www.nbcnews.com/business/consumer/lawmakers-grill-mylan-ceo-fdaepipen-price-hike-n651201.
83 Development & Approval Process (Drugs), FDA, (Jan. 29, 2016),
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/.
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labeling.87 This CDER team does not actually test the drug itself; rather,
it conducts research in the areas of quality, safety, and effectiveness
standards to determine if the drug’s health benefits outweigh its known
risks.88
Once the drug’s quality, safety, and effectiveness standards have been
established, the burden shifts to the drug company, or a sponsor, to
perform laboratory and animal tests in order to determine the likelihood
that it will be safe and effective in humans.89 From there, the company
can begin to test the drug on humans to determine whether it is safe when
used to treat a disease and whether it provides a real health benefit.90 The
need for an agency to regulate the drugs available in the American
market to consumers is paramount in order to ensure that Americans are
not unknowingly consuming harmful drugs.

i. Generic Drug Approval Process
Many new drugs are frequently under patent protection during
development, and oftentimes throughout the approval process.91 This
patent protects the company or sponsor’s investment in the drug’s
development by giving them the sole right to sell the drug while the
patent is in effect.92 A patent usually guarantees market exclusivity for a
drug for twenty years.93 Additionally, this also incentivizes companies to
undergo expensive research and design costs since they are likely to
recoup the cost through utilizing their patents.94 In an article on patent
protection strategies and market exclusivity in the pharmaceutical
industry, leading scholars found that “skyrocketing research costs have
resulted in an increased dependence on market exclusivity as a means of
maintaining growth and profitability.”95 Without a patent system, such as
the one the United States currently employs, it is likely many companies
would steal the formulas of newly-approved drugs and manufacture and
sell them at a much lower cost. This would create a risk for a black
market, the sale of unapproved drugs, and the overall safety of the drugs
87

Id.

88Development

& Approval Process (Drugs), FDA, (Jan. 29, 2016),
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/.
89 Id.
90 Id.
91 Id.
92 Id.
93 Himanshu Gupta, Suresh Kumar, Saroj Kumar Roy, R.S. Gaud, Patent Protection Strategies, J.
PHARM. BIOALLIED SCI., (Mar. 2010), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146086/.
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consumers are able to purchase. That is why once the patent, or some
other period of exclusivity, on a brand-name drug expires, manufacturers
can then apply to the FDA to sell generic versions of the drug.96 The
purpose of generic drugs is to provide a safe, effective, low-cost
alternative to American consumers.97 A generic drug is comparable to an
“innovator” or “brand-name” drug in dosage form, strength,
administration, quality, performance characteristics, and intended use.98
When generic drug manufacturers apply for FDA approval, their
applications are considered “abbreviated” because they are generally not
required to include laboratory, animal, and clinical data to establish
safety and effectiveness. 99 Instead, generic drug applicants must
scientifically demonstrate that their drug is bioequivalent, or performs in
the same manner as the brand-name drug.100 As of February 27, 2017,
the FDA held that one way scientists can determine bioequivalence is by
measuring the time it takes the generic drug to reach the bloodstream in
twenty-four to thirty-six healthy volunteers.101 The generic drug must
deliver the same amount of active ingredients into a patient’s
bloodstream in the same amount of the time as the brand-name drug in
order to be approved.102 Due to these very stringent requirements, as of
July 1, 2016, the FDA had 4,036 generic drug applications awaiting
approval and the median time for the FDA to approve a generic drug is
forty-seven months. 103 As of 2011, more than seventy percent of
prescriptions filled in the United States were for generic drugs.104 By
comparison, the European Medicines Agency (Europe’s version of the
FDA) has just twenty-four generic drugs waiting approval.105
The extreme backlog of drugs waiting FDA approval is not by chance,
however. Many companies have been trying to create a generic brand of

Id.
Abbreviated New Drug Application (ANDA): Generics, FDA, (Feb. 27, 2017),
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/A
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104 Bill Mears, High Court Sides With Generic Drug Makers in Narrow Ruling, CNN, (June 23,
2011), http://www.cnn.com/2011/HEALTH/06/23/scotus.generic.drugs/.
105 Sydney Lupkin, FDA Fees On Industry Haven’t Fixed Delays In Generic Drug Approvals, NPR
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epinephrine auto-injectors at a lower price than EpiPen.106 In March
2016, generics giant Teva Pharmaceuticals’ generic version of EpiPen
was rejected by the FDA and that its launch would be significantly
delayed. 107 Adamis Pharmaceuticals Corporation proposed an
alternative to the EpiPen, an epinephrine injection Pre-filled Single Dose
Syringe (“PFS”) product, whose approval was delayed by the FDA in
June of 2016.108 Mylan too has expressed a desire to manufacture a
generic version of the EpiPen.109 Mylan has said it will offer a $300
generic version at some point in 2017, however, because Mylan also
makes the brand-name product, it won’t have to wait in line behind other
pending generics.110

ii. Generic v. Brand-Name Drug Labeling Issues
In 2011 the Supreme Court of the United States of America ruled that
generic drug makers could not be held liable for failing to warn patients
about the risks of their products because the companies had no control
over what the warning labels said.111 In the 2011 case PLIVA v. Mensing,
two similar cases from lower courts were consolidated.112 Both cases
involved consumers who brought suit against generic drug
manufacturers, alleging their long-term use metoclopramide (a drug used
to treat heartburn) caused them to develop tardive dyskinesia
(involuntary movements of the tongue, lips, face, trunk, and
extremities).113 The plaintiffs argued brand-name drug makers have a
responsibility to change a label whenever they discover new important
information about a drug, and generic manufacturers are required to
follow suit.114 However, in delivering the opinion of the court, Justice
Thomas wrote, “it is beyond dispute that the federal…regulations that
apply to brand-name drugs…are meaningfully different than those that
Yaacov Benmeleh, Mylan’s EpiPen Boosted as FDA Sees Holes in Teva Application,
BLOOMBERG (Mar. 1, 2016), https://www.bloomberg.com/news/articles/2016-03-01/mylan-sepipen-gets-boost-as-fda-spots-holes-in-teva-application?cmpid=yhoo.headline.
107 Id.
108 Mark Flather & Mark Gundy, Adamis Pharmaceuticals Receives Complete Response Letter
From FDA For Its Epinephrine Pre-Filled Syringe NDA, CNBC (Jun. 6, 2016),
https://www.cnbc.com/2016/06/06/globe-newswire-adamis-pharmaceuticals-receives-completeresponse-letter-from-fda-for-its-epinephrine-pre-filled-syringe-nda.html.
109 Sydney Lupkin, FDA Fees On Industry Haven’t Fixed Delays In Generic Drug Approvals, NPR,
(Sept. 1, 2016), http://www.npr.org/sections/health-shots/2016/09/01/492235796/fda-fees-onindustry-havent-fixed-delays-in-generic-drug-approvals.
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apply to generic drug[s]…. [I]t is the special…regulation of generic
drugs that allowed the generic drug market to expand, bringing more
drugs more quickly and cheaply to the public.”115 This 2011 decision
split along ideological lines and has been highly scrutinized and praised
by various parties.116 Proponents of the ruling appreciate the tradition of
limiting the barriers generic drug manufacturers must pass through in
order to bring more drugs quickly and cheaply to the market to service
the needs of those consumers who cannot wait and cannot afford brandname drugs.117 Opponents of the ruling argue it increases the risk of
harm to consumers due to inadequate warnings on generic drugs.118
In an op-ed piece for Fox News Health, Dr. Jennifer Brokaw, a
practicing emergency physician for over fifteen years and founder of
C2it, wrote about how she once inadvertently used a generic brand of an
epinephrine drug that she was unfamiliar with.119 When she injected the
drug she gave the patient ten times the amount of epinephrine than she
had intended to because she assumed the generic brand was diluted, and
it was not.120 This creates an issue as to whose negligent action caused
the graver harm: the generic drug’s lack of labeling warning users that it
is not diluted, or the doctor’s failure to check?
This “labeling” issue is directly related to children’s use of epinephrine
autoinjector drugs. Many children with serious allergies are taught to use
the EpiPen, and are often given prescriptions strictly for the use of
EpiPens, and not a generic or substitute brand, because they know how to
use EpiPens should they ever go into anaphylactic shock.121 Proponents
of policies such as this argue limiting children’s use of epinephrine
autoinjectors to the EpiPen will limit a child’s risk for using the drug the
wrong way.122 Opponents of these policies argue this increases the
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Bills Mears, High Court sides with generic drug makers in narrow ruling, CNN (June 23, 2011),
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demand for, and thus the price of, EpiPens, making it unaffordable to
many consumers.123
As previously mentioned, the concern for the lack of generic
competition in the epinephrine autoinjector market encompasses
bipartisan support. Five United States Senators, Richard Blumenthal (DCT), Charles Grassley (R-IA), Rob Johnson (R-WI), Amy Klobuchar (DMN), and Patrick Leahy (D-VT), wrote to the FDA on August 24, 2016,
inquiring as to why generic versions of the EpiPen had been subjected to
additional questioning by the FDA and had not yet been approved.124
This only furthers the contention that the current system is broken. The
incredible backlog (of both generic and brand-name) drugs awaiting FDA
approval has increased both the risks and prices for consumers.
The combination of these two government regulations – the FDA
approval process and SAEEA – created an enormous problem for the
very consumers these regulations intended to protect. By mandating that
all schools purchase FDA-approved epinephrine drugs, and by creating
an invasive and complex approval process for epinephrine drugs, the
government has essentially allowed Mylan to obtain a monopoly over the
drug. This has enabled Mylan to skyrocket its prices making the lifesaving drug very unaffordable.

D. Legal Background on Generic Drug Alternatives
While Mylan, epinephrine autoinjector drugs, and generic drug
alternatives have been the subject of much litigation in the United States
legal system, this Note will focus on the 2014 United States District
Court case JHP Pharmaceuticals v. Hospira. 125 However, it is first
imperative to understand the nature of recent case law before JHP, in
respect to the changes to healthcare law after the Obama administration.
On March 23, 2010, President Barack Obama signed into law the
Patient Protection and Affordable Care Act (“ACA”), which included an
approximately 900-page law relating to sweeping modifications to the
health care system as a whole.126 The law’s numerous provisions also
brought important changes to particular aspects of the highly regulated
Senators Ask FDA to Account for Any Alternatives to the EpiPen Amid Product Cost Increases,
SENATE (Aug. 24, 2016), http://www.grassley.senate.gov/news/news-releases/senators-ask-fdaaccount-any-alternatives-epipen-amid-product-cost-increases (last visited Apr. 9, 2017).
124 Grassley, supra note 122.
125 JHP Pharmaceuticals v. Hospira, 52 F.Supp.3d 992 (C.D. Cal. 2014).
126 Carolyne R. Hathaway, John R. Manthei, and Elizabeth D. Meltzer, A Brave New World: The
U.S. Food and Drug Administration’s Newfound Authority for Regulation of Follow-on Biologics,
3 BLOOMBERG FIN. L.P. 5, (2010), https://www.lw.com/thoughtLeadership/fda-new-authorityover-follow-on-biologics.
123

CONSUMERS IN SHOCK

Vol. 16 Issue 1 DEPAUL BUSINESS & COMMERCIAL LAW JOURNAL

43

pharmaceuticals industry, specifically impacting the world of brand and
generic drug products. 127 The Biologics Price Competition and
Innovation Act of 2009 (“BPCIA”) within the ACA was meant to
rearrange the landscape for biologic product innovators and companies
seeking to market follow-on biologic products.128 BPCIA attempts to
balance the interests of innovators in recouping their large investment in
research, testing, and regulatory approval of innovative biologic
products, with the public’s interest in faster market entry and reduced
prices for competing follow-on biologics. BPCIA created a new
regulatory pathway, by which the FDA could approve a biologic product
as “biosimilar to” a “reference product” 129 that was itself approved under
the full, traditional pathway under the FDA. 130 Through this new
pathway, Congress established procedures to control and streamline
patent litigation between the biosimilar applicant and the reference
product, triggered by the filing of an application under the new
abbreviated pathway.
On May 5, 2015, Amgen, Inc. (“Amgen”) filed an emergency motion
for an injunction to prevent Sandoz, Inc. (“Sandoz”) from marketing,
selling, or importing into the United States ZARXIO®, its biosimilar
product. 131 The Northern District of California then issued a panel
opinion on July 21, 2015.132 The parties each filed petitions for en banc
review of aspects of that opinion.133 In its opinion, the Federal Circuit
extended the injunction through September 2, 2015.134 On October 15,
2015 Amgen officially filed suit against Sandoz for the requested
injunction.135 The case involved the first and only approved biosimilar
product, Sandoz’s drug called Zarxio (a filgrastim product that helps the
body make white blood cells after receiving cancer treatments), which
referenced Amgen’s filgrastim drug called Neupogen in order to be
approved.136 The Northern District of California ruled that BPCIA's
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notice of commercial marketing provision is mandatory and can only be
given after FDA licensure of a biosimilar.137
On
March
21,
2016,
Amgen
filed
a brief opposing
Sandoz’s request that the Supreme Court overturn the Northern District
of California’s ruling that BPCIA’s notice of commercial marketing
provision is mandatory and can only be given after FDA licensure of a
biosimilar product.138 Amgen filed a certiorari cross-petition asking that
should the Court decide to review the commercial marketing ruling, it
should also review and overturn the Northern District of California’s
ruling that the patent dance information exchange procedures of the
BPCIA are optional.139
This legal background sets the stage for the other factors that were
going on with the law and healthcare industry in general regarding the
many changes that occurred during the Obama administration. The
ACA, BPCIA, and case law filed during these administrative changes are
important to note when analyzing the JHP Pharmaceuticals opinion.

III. JHP PHARMACEUTICALS V. HOSPIRA OPINION
In JHP Pharmaceuticals v. Hospira, 140 Plaintiff JHP
Pharmaceuticals, LLC (“JHP”), manufacturer of epinephrine injectable
products, brought suit against Defendants Hospira, Inc. and American
Regent, Inc. (“Hospira”), a competitor alleging misleading labeling. As
previously discussed, labeling is critical to the manufacturing and selling
of drugs. This is because companies sacrifice a much greater cost to
obtain “brand-name” drug status as opposed to “generic” drug status,
which is reflected in the price companies can sell their products at.
Therefore, as this section will discuss, the JHP opinion further
complicates Mylan’s monopoly over the epinephrine autoinjector market.

James C. Shehan, Amgen Asks the Supreme Court to Reject Challenge to Ruling that Notice of
Commercial Marketing is Mandatory, But Asks for Review of Patent Dance Ruling Just in Casei,
FDA L. BLOG, (Mar. 28, 2016),
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A. Facts of the Case
JHP submitted a New Drug Application (“NDA”) for its one-milliliter
and thirty-milliliter injectable epinephrine products to the FDA under the
brand name “Adrenalin.”141 On December 7, 2012, the FDA granted JHP
approval to market and sell the one-milliliter version of Adrenalin.142
JHP alleged that it invested millions of dollars in complying with the
FDA approval process.143 JHP also alleged, and Hospira did not dispute,
that Hospira was engaged in the business of selling injectable epinephrine
products, which were not FDA-approved. 144 The bulk of JHP’s
complaint alleged that Hospira misled the public in four different ways:
(1) by representing that their products were FDA-approved when they
were not, (2) by advertising their products as “safe” and “effective,” (3)
by misleading as to the legality of their products, and (4) by misleading
the public into thinking that JHP’s product is more dangerous than the
generic brands.145 JHP asserted the claims against Hospira for each of
the aforementioned reasons as in violation of the Lanham Act,146 which
forbids false or misleading advertising.147

B. Court’s Holding
The United Stated District Court held JHP’s claim that the
competitor’s packaging was misleading by saying their non-FDA
approved injectable epinephrine products were safer than the JHP’s
product was not viable. The court wrote:
[JHP’s] fundamental argument with regard to FDA approval is that it is a
sort of ‘Good Housekeeping Seal’ for pharmaceuticals: it is the
government's imprimatur on a product, indicating quality, safety, and
desirability. Although some drugs may be lawfully sold without FDA
approval, if a product has been approved, consumers may take some
assurance that it has been properly tested and meets the agency’s
minimum quality standards. This makes an FDA-approved product a
more attractive product, whether at the wholesale, retail, or end user
level. But it can also be expensive to get approval for a drug, so a
company that chooses to invest in getting approval may operate at a
competitive disadvantage if other companies can falsely represent to the
Id. at 996
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public that their unapproved products are FDA-approved. Thus,
representations that a drug is approved when it is not undermine the
Lanham Act’s public policy goals both by confusing consumers and by
enabling unfair competition by producers who have not bothered to get
FDA approval.148

The court dealt with JHP’s four allegations regarding the various
arguments that Hospira misled the public, in four different ways. 149
Regarding the first instance in which JHP asserts Hospira misled the
public, the court held that there is a large difference between a company
making an overtly false statement and, merely misleading in context.150
Regarding the second instance in which JHP asserts Hospira misled the
public, the court held that the issue was not that Hospira chose to market
their product as “safe” or “effective,” rather, that Hospira overtly misled
the consumer by labeling their product as “FDA-approved” when it was
not. 151 Regarding the third instance in which JHP asserts Hospira
mislead the public, the court held this was a claim with regard to legality
requirements that is within the primary jurisdiction of the FDA. 152
Finally, the fourth way in which JHP asserts Hospira misled the public
was by omitting from the labeling of their product certain injection
location and adverse reaction information.153 JHP’s product must carry
this labeling as apart of its FDA approval requirements.154 However, JHP
alleges that such labeling misleads the public into thinking that JHP’s
product is more dangerous than the generic brands. 155 The court
dismissed this claim because the Lanham Act requires a showing of facts
regarding the labeling that JHP did not properly plead.156

IV. ANALYSIS
A. Policy Implications and Legal Analysis
In JHP Pharmaceuticals v. Hospira JHP argued Hospira mislead the
public by not including on their packaging and labeling all of the
warnings that JHP was required to include under the terms of the FDA
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approval.157 Therefore, JHP alleged, Hospira created the impression that
their product was less safe than JHP’s because it came with more
warnings, when in fact, JHP believed, the opposite was true because
JHP’s drug was approved by the FDA and Hospira’s was not.158 The
court dismissed this claim because they believed JHP did not show that
this message was actually transmitted to the consumer, and because JHP
did not successfully prove that because the FDA did not approve
Hospira’s product it was somehow less safe.159 If Hospira’s product was
actually found to be less safe than JHP’s, then the misleading labeling
claim would have succeeded. Therefore, the claim was dismissed.160
While the court never determined whether or not Hospira’s drug was
“safe,” their failure to determine that Hospira’s drug was any less safe
was in itself an endorsement of non-approved drugs. If the court was
truly concerned that Hospira was somehow trying to trick the public, it
would have found for JHP. Further, if the court had found that Hospira’s
conduct was in someway unsafe to American consumers, it would have
done something to prevent Hospira from continuing this harmful conduct.
With respect to the surviving clams, the court reiterated the Supreme
Court decision that the Lanham Act is a discrete regulatory scheme, with
neither statute precluding claims made under the other.161 The court
analyzed JHP’s surviving allegations with this in mind.162 With respect
to Hospira’s alleged misrepresentations of FDA approval, the court found
no preclusion, explaining that falsely representing FDA approval may
confer a competitive disadvantage upon the approved drug.163 Thus,
false representations of approval “undermine the Lanham Act’s public
policy goals both by confusing consumers and by enabling unfair
competition by producers who have not bothered to get FDA
approval.”164
As for JHP’s claim that the Hospira misrepresented the legality of their
products, the court explained the evaluation of this claim “directly
implicates the FDA’s rulemaking authority,” and required the expertise
of the FDA to resolve.165 The court noted that “[t]he determination of
whether a drug is ‘new,’ and whether it can be lawfully marketed under

JHP Pharmaceuticals. 52 F.Supp.3d at 992.
Id. at 996-97.
159 Id. at 1005-6.
160 Id.
161 JHP Pharmaceuticals. 52 F.Supp.3d at 998.
162 Id.
163 Id. at 1000.
164 Id.
165 Id. at 1004.
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the United States Federal Food, Drug, and Cosmetics Act (“FDCA”),166
involves complex issues of history, public safety and administrative
priorities that Congress has delegated exclusively to the FDA.”167 Unlike
JHP’s allegations of misrepresentations of FDA approval, its allegations
based on stations of “legality” would be precluded in the absence of prior
review by the FDA.168

1. FDA-Approved Drugs in the Market
The holding in JHP Pharmaceuticals169 has tremendous impact on the
legality surrounding non-FDA approved drugs on the market. The
court’s finding that there was no sufficient proof to show that an
unregulated drug was any less safe than a regulated drug, 170 speaks
volumes to the policy issues of FDA approval. The entire purpose of the
FDA is to conduct research on a drug’s quality, safety, and effectiveness
to determine whether a drug’s health benefits outweigh its known risks
before allowing that drug to enter the market.171 In JHP Pharmaceuticals
the court essentially found that an unregulated drug was not any less safe
than a regulated drug.172 This could lead to questions about the actual
purpose of the FDA. If an unregulated drug was not necessarily any less
safe than a regulated drug, why would any company waste the time and
resources to gain FDA approval in the first place?

2. FDA Approval Process Creates a Monopoly
The FDA approval processes for new drugs create a de facto monopoly
on approved drugs when interfering legislation, such as the SAEEA,
complicate the market. It is clearly important to have one consistent
governing entity to regulate and evaluate drugs, especially a drug used by
so many children. However, if a federal court can undermine the
legitimacy of an administrative agency, this presents an issue.
Uniformity among different bodies of government is critical to the
forefront of democracy. However, uniformity is lacking where the
judiciary steps in to make a definitive ruling one way or the other.
Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, 111 Stat. 2296
(1997).
167 JHP Pharmaceuticals , 52 F.Supp.3d at 1002.
168 Id.
169 Id. at 992.
170 Id. at 996.
171 Development & Approval Process (Drugs), FDA, (Jan. 29, 2016),
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/.
172 JHP Pharmaceuticals, 52 F.Supp.3d at 996.
166
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Courts should follow the reasoning in JHP Pharmaceuticals that where
there is no definitive proof the non-FDA approved drug should not be
considered any less safe. If this reasoning is applied, companies awaiting
FDA approval will not be punished for trying to access the market.
Hopefully, this would allow a company to sell non-FDA approved
epinephrine autoinjectors to consumers that desperately need the lifesaving drug.

3. Economic and Legal Effects of Federal Overregulation
Nonetheless, if Mylan’s competitors advertise their products as being
as safe and as effective as the EpiPen, despite no FDA approval, this
could help lower costs for epinephrine autoinjectors across the country.
However, federal mandates such as SAEEA that require FDA approval
for a very large percentage of epinephrine autoinjector sales, still feed
into this de facto monopoly issue. Unfortunately, a judicial ruling on this
issue can only go so far if the regulations by other branches of
government do not reflect the current atmosphere. Even if the Trump
Administration were to lift the SAEEA requirements, EpiPen has already
accessed the system. Even if schools were no longer required to store
epinephrine autoinjectors, it is unlikely they would stop stocking the,
since many students’ health still rely access to these autoinjectors.
While hindsight is always twenty-twenty, hopefully the Mylan EpiPen
monopoly can, at the very least, serve as a lesson to the federal
government and advocates for overregulation. It is evident that the
government went too far in attempting to fix the problem of children
going into anaphylactic shock and needing assistance with an epinephrine
autoinjector. Two regulations that, on their face, seem necessary (an
FDA approval process that ensures consumers receive safe drugs and
mandating that schools carrying epinephrine autoinjectors) thwarted the
very success that they were trying to achieve. Four years after the
enactment of the SAEEA, EpiPens have quadrupled in price becoming
nearly impossible for consumers to purchase. Legislators should be very
weary of the long-term effects of legislation, and continue to analyze how
pending legislation will be affected by policies and procedures
implemented by other branches of government. This only reiterates the
importance of the judiciary to answer the call and address the mistakes
made by the legislative and executive branches.
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V. IMPACT
This section discusses the impact of the court’s ruling in JHP
Pharmaceuticals v. Hospira.173 First, it explores the impact the case has
had on the field of healthcare.174 Second, it explores the case’s impact on
field of education.175
A. Impact on Healthcare
The holding in JHP Pharmaceuticals176 impacts how business works
in the healthcare industry because ensuring that consumers have drugs
available to them that are equally safe and affordable is critical, and,
arguably, the most important impact of this subject. The ways in which
drug manufacturers can manipulate the market through favorable
government intervention poses significant problems for consumers. If a
drug manufacturer has a monopoly on over ninety percent of the
market177 then a consumer will reasonably believe that this drug is the
most superior drug available to them. It is one thing for a manufacturer
to use smart business and marketing tactics, such as giving away free
products to schools in order to increase brand recognition178, or by only
selling the product in two-packs effectively doubling their price.179 The
most successful companies in American history have used tactical
business maneuvers throughout history. Well-known companies from
Kraft to General Mills to Proctor & Gamble have adopted this strategy.180
However, it is an entirely different situation when a manufacturer gains
market control because of government favorability. Furthermore, the
stakes are even higher when that manufacturer is creating a life-saving
drug, rather than when a company is manufacturing macaroni and cheese
or toothpaste.
Id. at 992.
See infra notes 174-180 and accompanying text.
175 See infra notes 181-185 and accompanying text.
176 JHP Pharmaceuticals, 52 F.Supp.3d at 992.
177 Ben Popken, Lawmakers Accuse Mylan CEO of ‘Rope-a-Doping’ on EpiPen Prices, NBC
NEWS, (Sept. 21, 2016), http://www.nbcnews.com/business/consumer/lawmakers-grill-mylan-ceofda-epipen-price-hike-n651201.
178 Carolyn Y. Johnson and Catherine Ho, How Mylan, the EpiPen company, maneuvered to create
a virtual monopoly, CHI. TRIB. (Aug. 25, 2016), http://www.chicagotribune.com/business/ct-mylanepipen-monopoly-20160825-story.html.
179 Ben Popken, Lawmakers Accuse Mylan CEO of ‘Rope-a-Doping’ on EpiPen Prices, NBC
NEWS, (Sept. 21, 2016), http://www.nbcnews.com/business/consumer/lawmakers-grill-mylan-ceofda-epipen-price-hike-n651201.
180 Brad Tuttle, The Power of Freebies: Why Companies Pay to Give Free Samples to Supermarket
Customers, BUS. TIME, (Feb. 17, 2011), http://business.time.com/2011/02/17/the-power-offreebies-why-companies-pay-to-give-free-samples-to-supermarket-customers/.
173
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B. Impact on Legislation
The holding in JHP Pharmaceuticals181 impacts how overregulation of
a field may thwart the very efforts the proposed legislation is trying to
help. The overregulation of epinephrine drugs essentially drove up the
price making them nearly unaffordable for those who need them most.
Businesses who create the best products deserve the chance to prove that
to the market on their own, and not be overshadowed by a regulationinduced monopoly.
In order to ensure that consumers have access to the best, most
efficient, most superior, and, in the case of drugs and medicine, most
affordable products, the government should not intervene and
overregulate the market. In the case of the EpiPen, the government did
so in all three branches: the executive, the legislature, and the judiciary.
First, the FDA’s lengthy and over-complicated approval process makes it
nearly impossible for generic drug manufacturers to create safe and
affordable alternatives to the EpiPen.182 Second, the School Access to
Emergency Epinephrine Act enacted by Congress in 2013 heavily
influenced by Mylan, essentially allowed Mylan to acquire a monopoly
over the epinephrine autoinjector market by offering financial incentives
to states who required all schools to stock the drug, knowing full well
that the majority of schools were only familiar with the EpiPen.183 Third,
a federal court, failed to find that a non-approved FDA drug was any less
safe than an FDA-approved drug,184 essentially undermining the entire
legitimacy and purpose behind the agency. The court, essentially deemed
the non-FDA approved drug just as safe as FDA-approved drug, yet still
did not make it possible for a non-FDA approved drug to enter the
market.
The purpose of the federal judiciary system is to evaluate laws – to
interpret the meaning of the laws, apply laws to individual cases, and to
decide if laws violate the Constitution.185 The beauty of the system of
checks and balances in the United States government is that no one
branch of government is sovereign. If the judiciary finds a flaw within a
law enacted by Congress when applying that law to a particular case, it
JHP Pharmaceuticals, 52 F.Supp.3d at 992.
Development & Approval Process (Drugs), FDA, (Jan. 29, 2016),
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/.
183 Carolyn Y. Johnson and Catherine Ho, How Mylan, the EpiPen company, maneuvered to create
a virtual monopoly, CHI. TRIB, (Aug. 25, 2016), http://www.chicagotribune.com/business/ct-mylanepipen-monopoly-20160825-story.html.
184 JHP Pharmaceuticals v. Hospira, 52 F.Supp.3d 992, 997 (C.D. Cal. 2014).
185 Branches of Government, USA, https://www.usa.gov/branches-of-government (last visited Mar.
27, 2017).
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should further analyze whether or not the legislation is inconsistent with
the Constitution. While the purpose of the FDA is to ensure only safe
drugs enter the market place, the JHP ruling found a non-FDA approved
drug was no less safe than an FDA-approved drug. Therefore, the court
should not have stopped its analysis there. The specifics of the FDA
approval process should be called into question and analyzed by the
federal court system.

VI. CONCLUSION
In conclusion, the overregulation of the epinephrine autoinjector
market by the federal government caused Mylan to acquire a monopoly
on the EpiPen, increasing the cost of the product for consumers. This
overregulation was caused by the United States Congress in the passing
of the SAEEA, by mandating that states must comply with this law, and
by the over-stringent FDA approval process for alternative epinephrine
autoinjector drugs. Further, this problem has been exacerbated by the
United States Federal Court system as seen in JHP Pharmaceuticals. If
JHP was unable to allege any facts that Hospira’s drug was either unsafe
or ineffective and therefore the court allowed for its legal sale, then the
federal court finding is inconsistent with the purpose of a federal
government agency. Drugs that are not found to be unsafe or ineffective
should therefore be approved by the FDA, or, at the very least, be
approved to market to consumers.
There have been two major proposals to deal with the EpiPen
monopoly and price surge. Advocates on the right think the overly
stringent FDA regulations and long approval process are to blame. At his
first address to a joint session of Congress, President Trump said, “our
slow and burdensome approval process at the Food and Drug
Administration keeps too many advances…[from] reaching those in
need.”186
Advocates on the left tend to think more government regulation will
fix the problems with previous government regulation. When she was
running for President, Mrs. Clinton claimed the EpiPen price hikes
showed the need for price controls, and she said she would require drug
makers to “prove that any additional costs are linked to additional patient
benefits and better value.”187
Donald J. Trump, Donald Trump’s Congress speech, CNN, (Mar. 1, 2017),
http://www.cnn.com/2017/02/28/politics/donald-trump-speech-transcript-full-text/.
187 Hillary R. Clinton, Hillary Clinton Statement on EpiPen Pricing, HILLARY CLINTON,
https://www.hillaryclinton.com/briefing/statements/2016/08/24/hillary-clinton-statement-onepipen-pricing/ (last visited Mar. 27, 2017).
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There are clearly many proposed solutions to this problem, as the
problem itself harbors bipartisan support.
Both Republican and
Democratic lawmakers have the same end goal: to make epinephrine
autoinjector drugs more affordable to families who desperately need this
life-saving drug. Either loosening the reigns on the FDA approval
process, or allowing for other bodies of government (such as the federal
courts) to approve the sale of these products are viable alternatives. This
would allow for two products containing nearly the same ingredients,
intended to be used for the exact same purposes, to be sold with similar
labeling. This would allow the free market system to naturally weed out
the inferior of the two products based on consumer preferences. So long
as all of the products were considered safe and effective by the FDA,
then the consumers could drive the market based on their preferences
between drug manufacturers and would not be limited only by what the
federal government allows them to choose from. Prices would drop and
product efficiency would increase.
Based on these reasons, courts should decline to follow the overall
ruling in JHP Pharmaceuticals.188 Holding that the court is unable to
decide cases based on a separate federal agency is simply a waste of
litigation, which could have been used to better their products, which is
ultimately better for society. However, courts should consider the line of
reasoning employed in JHP Pharmaceuticals in that where there is no
proof that a non-FDA approved drug is any less safe than an FDAapproved drug, the non-approved drug should not be precluded from
entering the market because this will only increase the competition of a
healthy market, providing more and better options for consumers.

188

JHP Pharmaceuticals, 52 F.Supp.3d at 992.

